Abstract
PURPOSE
Transforming growth factor beta-1 (TGF-β1) is a profibrotic cytokine used as an early
biomarker to develop radiation-induced fibrosis (RIF). This study aimed to compare
TGF-β1 serum levels in early-stage breast cancer patients treated with whole-breast
radiation therapy (WBRT) plus boost versus accelerated partial breast irradiation
(APBI) using multicatheter interstitial brachytherapy.
METHODS AND MATERIALS
This clinical trial study was conducted on 20 women with early-stage breast cancer
after breast-conserving surgery candidate for adjuvant radiotherapy in Golestan hospital,
Ahvaz, in 2021. In one group APBI with high-dose-rate brachytherapy (n = 10), the other group WBRT with external beam radiation plus boost (n = 10) was performed. Serum level of TGF-β1 was evaluated before radiotherapy, immediately
after the end of radiotherapy and three months after the end of radiotherapy by Enzyme-linked
immunosorbent assay technique (ELISA).
Results
Median serum TGF-β1 level before radiotherapy was not significantly different between
the two groups (p = 0.971). In both APBI and WBRT groups, serum TGF-β1 levels significantly decreased
immediately after radiotherapy compared to before treatment (p = 0.005 and p = 0.007, respectively); But three months after radiotherapy, serum TGF-β1 levels
increased significantly in the WBRT group (40.50 to 77.41 pg/mL; p = 0.017), while no significant change was observed in the APBI group (24.75 to 30.50
pg/mL; p = 0.332).
ConclusionS
Higher TGF-β1 values in the WBRT group after radiotherapy can be used as an early
and vital biomarker in this treatment, and this data may corroborate links between
TGF-beta1 and fibrosis and fibrosis rates between APBI and WBRT; It also shows the
preference for using the brachytherapy technique in this group of patients. However,
due to the small number of samples, definitive conclusions require further prospective
studies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Breast cancer statistics, 2019.CA Cancer J Clin. 2019; 69: 438-451
- Accelerated partial breast irradiation with interstitial multicatheter brachytherapy after breast-conserving surgery for low-risk early breast cancer.The Breast. 2020; 52: 45-49
- Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.Lancet Oncol. 2015; 16: 47-56
- Comparison of local recurrence among early breast cancer patients treated with electron intraoperative radiotherapy vs hypofractionated photon radiotherapy an observational study.Front Oncol. 2018; 8: 207
- American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy.Brachytherapy. 2017; 16: 919-928
- 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.Lancet North Am Ed. 2016; 387: 229-238
- Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.J Clin Oncol. 2008; 26: 1239-1246
- The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation.Brachytherapy. 2018; 17: 154-170
- Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2017; 18: 259-268
- Multicatheter interstitial brachytherapy versus intensity modulated external beam therapy for accelerated partial breast irradiation: a comparative treatment planning study with respect to dosimetry of organs at risk.Radiother Oncol. 2017; 122: 17-23
- Cosmetic outcome and chronic breast toxicity after intraoperative radiation therapy (IORT) as a single modality or as a boost using the Intrabeam® device: a prospective study.Ann Surg Oncol. 2017; 24: 2547-2555
- Radiation-induced fibrosis in breast cancer: a protocol for an observational cross-sectional pilot study for personalised risk estimation and objective assessment.Int J Surg Protocols. 2019; 14: 9-13
- TGF-β and fibrosis in different organs—Molecular pathway imprints.Biochim Biophys Acta (BBA)-Mol Basis Dis. 2009; 1792: 746-756
- TGF-β1 is present at high levels in wound fluid from breast Cancer patients immediately post-surgery, and is not increased by intraoperative radiation therapy (IORT).PLoS One. 2016; 11e0162221
- Transforming growth factor β-1 (TGF-β1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study.Int J Radiat Oncol Biol Phys. 2013; 87: 1030-1036
- TGF-β1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis.Int J Cancer. 1999; 84: 155-159
- Breast-conserving surgery in breast cancer and intraoperative radiotherapy. Can we predict the fibrosis?.Cirugía Española (English Edition). 2019; 97: 517-522
- Perez & Brady's principles and Practice of Radiation Oncology.Lippincott Williams & Wilkins, 2013
- Recommendations from GEC ESTRO Breast Cancer Working Group (I): target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery.Radiother Oncol. 2015; 115: 342-348
- Influence of radiotherapy on immediate breast reconstruction after skin-sparing mastectomy. Before or after: does it matter?.Cirugía Española (English Edition). 2019; 97: 156-161
- TGF-β1 and TNF-α synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation.J Cell Commun Signal. 2019; 13: 369-380
- Resveratrol inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial-mesenchymal transition.Molecules. 2019; 24: 1131
- TGF-β1-induced epithelial–mesenchymal transition promotes monocyte/macrophage properties in breast cancer cells.Front Oncol. 2015; 5: 3
- Radiation fibrosis—Current clinical and therapeutic perspectives.Clin Oncol. 2012; 24: 657-672
- Pathogenetic mechanisms in radiation fibrosis.Radiother Oncol. 2010; 97: 149-161
- Role of transforming growth factor-β1 in triple negative breast cancer patients.Int J Surg. 2017; 45: 72-76
- Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer.Oncol Lett. 2016; 11: 4040-4044
- Transforming growth factor‑β, insulin‑like growth factor I/insulin‑like growth factor I receptor and vascular endothelial growth factor‑A: prognostic and predictive markers in triple‑negative and non‑triple‑negative breast cancer.Mol Med Rep. 2015; 12: 851-864
- Transforming growth factor-β: a therapeutic target for cancer.Hum Vaccin Immunother. 2017; 13: 1741-1750
- Biologic comparison of partial breast irradiation protocols.Int J Radiat Oncol Biol Phys. 2004; 60: 1393-1404
- Long-term cosmetic changes after breast-conserving treatment of patients with stage I–II breast cancer and included in the EORTC' boost versus no boost'trial.Ann Oncol. 2012; 23: 2591-2598
- Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: results of the Young boost trial.Radiother Oncol. 2018; 128: 434-441
- Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer–A study based on the EORTC trial 22881–10882′ boost versus no 'boost'.Eur J Cancer. 2008; 44: 2587-2599
Article info
Publication history
Published online: September 24, 2022
Accepted:
August 18,
2022
Received in revised form:
August 17,
2022
Received:
June 29,
2022
Footnotes
Disclosures: The present article is taken from the dissertation of the specialized residency course in radiotherapy. This research was financially supported by a grant (No. CRC-0022) from the vice-chancellor for Ahvaz Jundishapur University of Medical Sciences research affairs.
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
